

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOAL AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	2
INFORMATION SOURCES.....	2
ANALYST’S CREDENTIALS.....	3
RELATED BCC PUBLICATIONS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
PROJECTED GROWTH OF PEDIATRIC MARKETS	4
<i>SUMMARY TABLE GLOBAL TRENDS IN PEDIATRIC HEALTH CARE,</i> <i>THROUGH 2013 (\$ MILLIONS)</i>	4
<i>SUMMARY FIGURE GLOBAL TRENDS IN PEDIATRIC HEALTH</i> <i>CARE, BASED ON CONDITION, 2007-2013 (\$ MILLIONS)</i>	5
MARKET FORECASTS FOR SHORT-TERM ILLNESSES	5
ROTAVIRUS.....	5
EAR INFECTIONS	6
UPPER RESPIRATORY INFECTIONS	6
MARKET FORECASTS FOR CHRONIC ILLNESSES	6
ALLERGIES	6
ATTENTION DEFICIT DISORDERS.....	7
ASTHMA.....	7
AUTISM SPECTRUM DISORDERS.....	7
DIABETES	8
OBESITY	8
 CHAPTER THREE: OVERVIEW OF THE PEDIATRIC HEALTHCARE INDUSTRY	 9
<i>TABLE 1 PROJECTED PEDIATRIC PREVENTATIVE CARE COSTS</i> <i>FROM BIRTH THROUGH AGE 18 IN THE U.S., THROUGH 2013</i> <i>(\$ MILLIONS)</i>	9
PRENATAL CARE/IMPLICATIONS.....	9
INTERNATIONAL PRENATAL CARE/IMPLICATIONS	10
Low Birth Weight	10
NEWBORN CARE	11
CARE IN THE U.S.....	11
INTERNATIONAL NEWBORN CARE.....	12
Malnutrition.....	12
CHILDREN AGE 1 TO 6	12
CHILDREN AGE 7 TO 12	13
ADOLESCENT CHILDREN AGE 13 TO 18	13

ADOLESCENT REPRODUCTIVE HEALTH.....	14
SEXUALLY TRANSMITTED DISEASES	14
Human papillomavirus (HPV)	14
VACCINES/IMMUNIZATIONS.....	15
<i>TABLE 2 IMMUNIZATION SCHEDULE FOR CHILDREN FROM</i>	
<i>BIRTH TO 6 MONTHS</i>	<i>15</i>
<i>TABLE 3 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12</i>	
<i>MONTHS TO 4 TO 6 YEARS.....</i>	<i>16</i>
<i>TABLE 4 IMMUNIZATION SCHEDULE FOR CHILDREN AND</i>	
<i>ADOLESCENTS FROM 7 TO 18.....</i>	<i>16</i>
<i>TABLE 4 (CONTINUED).....</i>	<i>17</i>
VACCINE EFFICACY AND CONTROVERSY.....	17
IMPLICATIONS FOR FUTURE DEVELOPMENTS IN THE U.S.....	17
IMPLICATIONS FOR FUTURE ...(CONTINUED).....	18
 CHAPTER FOUR: SHORT-TERM ILLNESSES IN THE PEDIATRIC	
POPULATION.....	19
<i>TABLE 5 GLOBAL COSTS OF THREE PRIMARY SHORT-TERM</i>	
<i>ILLNESSES IN PEDIATRIC POPULATION, THROUGH 2013</i>	
<i>(\$ MILLIONS).....</i>	<i>19</i>
<i>FIGURE 1 GLOBAL COST OF PEDIATRIC SHORT-TERM ILLNESS,</i>	
<i>2008 AND 2013 (\$ MILLIONS).....</i>	<i>20</i>
OTITIS MEDIA (EAR INFECTIONS)	20
CAUSES OF OTITIS MEDIA.....	21
Allergies	21
Infection	21
Blockage	21
Nutrition and breastfeeding.....	21
TYPES AND SYMPTOMS	22
TREATMENT	22
Pharmacological intervention	23
Use of Prevnar	23
<i>TABLE 6 GLOBAL PRESCRIPTION COSTS FOR TREATMENT OF</i>	
<i>PEDIATRIC OTITIS MEDIA, THROUGH 2013 (\$ MILLIONS).....</i>	<i>24</i>
<i>TABLE 7 PRESCRIPTION COSTS FOR TREATMENT OF PEDIATRIC</i>	
<i>OTITIS MEDIA, IN THE U.S., THROUGH 2013 (\$ MILLIONS).....</i>	<i>24</i>
Surgical Intervention	24
Myringotomy	24
<i>TABLE 8 GLOBAL SURGICAL COSTS FOR MYRINGOTOMY IN</i>	
<i>PEDIATRIC PATIENTS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>25</i>
<i>TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S.</i>	
<i>PEDIATRIC PATIENTS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>26</i>
Adenoidectomy and Tonsillectomy.....	26

<i>TABLE 10 GLOBAL SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN PEDIATRIC PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	27
<i>TABLE 11 SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN U.S. PEDIATRIC PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	28
GASTROINTESTINAL ILLNESSES.....	28
ROTAVIRUS.....	28
Transmission	29
Symptoms.....	29
Treatment	29
Dehydration	29
Zinc	30
Vaccinations.....	30
Rotateq	30
Rotarix.....	31
<i>TABLE 12 GLOBAL VACCINATION FOR PEDIATRIC ROTOVIRUS, THROUGH 2013 (\$ MILLIONS)</i>	31
<i>TABLE 13 U.S. VACCINATION FOR PEDIATRIC ROTOVIRUS, THROUGH 2013 (\$ MILLIONS)</i>	31
GASTROESOPHAGEAL REFLUX	31
Treatment	32
Eliminate symptoms	32
Heal esophagus	32
Prevent complications.....	33
<i>TABLE 14 CURRENT TREATMENTS FOR GERD</i>	33
UPPER RESPIRATORY INFECTIONS	33
<i>TABLE 15 GLOBAL DIRECT COSTS OF PEDIATRIC UPPER RESPIRATORY INFECTIONS, THROUGH 2013 (\$ MILLIONS)</i>	34
<i>TABLE 16 DIRECT COSTS FOR PEDIATRIC UPPER RESPIRATORY INFECTIONS IN THE U.S, THROUGH 2013 (\$ MILLIONS)</i>	35
CAUSES AND SYMPTOMS	35
<i>TABLE 17 COMMON SYMPTOMS OF AN URI</i>	35
<i>TABLE 17 (CONTINUED)</i>	36
TREATMENTS.....	36
Increased Fluid Intake	36
Second-hand Smoke.....	36
Medications	37
ANTIBIOTIC TREATMENTS	37
Withdrawing Medicines	38
COMPLICATIONS.....	38
 CHAPTER FIVE: CHRONIC ILLNESSES IN THE PEDIATRIC POPULATION.....	 39

<i>TABLE 18 GLOBAL COST OF CHRONIC ILLNESSES IN THE PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	39
<i>TABLE 19 COST OF CHRONIC ILLNESSES IN U.S. PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	40
<i>FIGURE 2 PROJECTED COSTS FOR PEDIATRIC CHRONIC ILLNESSES IN THE U.S., THROUGH 2013 (\$ MILLIONS)</i>	41
CYSTIC FIBROSIS	41
ORIGINS OF THE DISEASE	41
DIAGNOSING CF	42
PREVALENCE	42
TREATMENT	43
Oscillating Positive Expiratory Pressure (PEP).....	43
High-Frequency Chest Wall Oscillation (HFCWO)	43
Medications	44
Pulmozyme	44
TOBI	44
Enzyme Treatments	44
<i>TABLE 20 GLOBAL SALES FOR PEDIATRIC CYSTIC FIBROSIS MEDICATIONS AND THERAPIES, THROUGH 2013 (\$ MILLIONS)</i>	45
<i>TABLE 21 U.S. SALES FOR PEDIATRIC CYSTIC FIBROSIS MEDICATIONS AND THERAPIES, THROUGH 2013 (\$ MILLIONS)</i>	45
<i>TABLE 22 U.S. SALES FOR CYSTIC FIBROSIS MEDICATIONS, BY COMPANY, THROUGH 2013 (\$ MILLIONS)</i>	46
Antibiotics	46
DIABETES	46
HISTORY	46
ORIGINS OF THE DISEASE	47
TYPE 1 DIABETES.....	48
TYPE 2 DIABETES.....	48
COMPLICATIONS.....	48
Hypoglycemia.....	48
Hyperglycemia	49
Ketoacidosis	49
DIAGNOSING DIABETES.....	49
Type 1 Diagnosis.....	50
Type 2 Diagnosis.....	50
Prediabetes	50
PREVALENCE	51
COMPLICATIONS OF PEDIATRIC DIABETES.....	51
Growth	52
Psychological Characteristics.....	52
Health Status.....	52
Family Dynamics.....	52
Outside Care	52

TREATMENTS.....	53
Glycemic Control	53
Types of Insulin	54
Long-Acting Insulins	54
Rapid Insulins	54
Intermediate-Acting Insulin.....	55
Short-Acting Insulin	55
ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES	55
Alternative Delivery Options	55
Insulin Pump.....	55
Insulin Pens	55
Inhaled Insulin.....	56
<i>TABLE 23 GLOBAL INSULIN MARKET, THROUGH 2013 (\$</i>	
<i> MILLIONS)</i>	56
<i>TABLE 24 INSULIN MARKET IN U.S., THROUGH 2013 (\$ MILLIONS)</i>	56
<i>TABLE 25 INSULIN APPROVED FOR CHILDREN AND</i>	
<i> ADOLESCENTS IN THE U.S.</i>	57
<i>TABLE 26 GLOBAL PEDIATRIC INSULIN MARKET, THROUGH 2013</i>	
<i> (\$ MILLIONS)</i>	57
<i>TABLE 27 PEDIATRIC INSULIN MARKET IN U.S., THROUGH 2013 (\$</i>	
<i> MILLIONS)</i>	58
ORAL AGENTS.....	58
<i>TABLE 28 SELECTED LIST OF MOST COMMONLY PRESCRIBED</i>	
<i> ORAL AGENTS</i>	58
<i>TABLE 28 (CONTINUED)</i>	59
NUTRITIONAL MANAGEMENT	59
PHYSICAL ACTIVITY.....	59
GLUCOSE MONITORING SYSTEMS	60
<i>TABLE 29 SELECTED LIST OF COMPANIES MARKETING GLUCOSE</i>	
<i> MONITORING TESTS</i>	61
Abbott Laboratories' New Technology	62
<i>TABLE 30 WORLDWIDE MARKET FOR BLOOD GLUCOSE</i>	
<i> MONITORING DEVICES, THROUGH 2013 (\$ MILLIONS)</i>	62
<i>TABLE 31 U.S. BLOOD GLUCOSE MONITORING MARKET,</i>	
<i> THROUGH 2013 (\$ MILLIONS)</i>	63
<i>TABLE 32 SELECTED GLOBAL BLOOD GLUCOSE MONITORING</i>	
<i> MARKET BY COMPANY, THROUGH 2013 (\$ MILLIONS)</i>	63
Pediatric Market.....	63
<i>TABLE 33 GLOBAL PEDIATRIC BLOOD GLUCOSE MONITORING</i>	
<i> MARKET, THROUGH 2013 (\$ MILLIONS)</i>	64
<i>TABLE 34 U.S. PEDIATRIC BLOOD GLUCOSE MONITORING</i>	
<i> MARKET, THROUGH 2013 (\$ MILLIONS)</i>	64
LOW-BIRTH WEIGHT	64
ORIGINS OF THE DISEASE	64

PREVALENCE	65
Consequences in the U.S.	66
Neurological Problems.....	66
Chronic Lung Disease.....	66
Hearing Loss	67
Retinopathy of Prematurity	67
DIAGNOSING LOW BIRTH WEIGHT.....	67
TREATMENT FOR LOW BIRTH WEIGHT	68
Retinopathy.....	68
COSTS OF LOW BIRTH-WEIGHT CHILDREN.....	69
MALNUTRITION	69
ORIGINS OF THE DISEASE	69
DIAGNOSING MALNUTRITION	70
MICRONUTRIENT DEFICIENCIES	70
<i>TABLE 35 EFFECTS OF MICRONUTRIENT DEFICIENCIES</i>	<i>71</i>
Vitamin A Deficiency.....	71
Iron Deficiency	71
Iodine Deficiency.....	71
Folic Acid.....	72
PREVALENCE	72
TREATMENTS.....	72
ADDRESSING MALNUTRITION IN THE U.S.	73
Successful National Nutrition Programs.....	73
Supplemental Nutrition Assistance Program	
(SNAP)	73
Women, Infants and Children (WIC)	74
ADDRESSING MALNUTRITION GLOBALLY	75
Nutriset.....	75
<i>TABLE 36 PROJECTED SALES OF PLUMPY'NUT, THROUGH 2013 (\$</i>	
<i>MILLIONS).....</i>	<i>76</i>
NEUROLOGICAL DISORDERS.....	76
ATTENTION DEFICIT DISORDER/ATTENTION DEFICIT	
HYPERACTIVITY DISORDER	77
ORIGINS OF ADHD	77
Brain Structures and Chemicals	77
Genetic Factors	78
Dietary Factors	78
PREVALENCE.....	78
DIAGNOSING ATTENTION DEFICIT/ATTENTION	
DEFICIT/HYPERACTIVITY DISORDERS.....	78
<i>TABLE 37 COMMON SYMPTOMS OF ADHD.....</i>	<i>79</i>
OTHER DISORDERS	79
<i>TABLE 38 ADDITIONAL DISORDERS SEEN IN CHILDREN WITH</i>	
<i>ADHD</i>	<i>80</i>

TREATMENT TYPES.....	80
Therapy.....	80
Pharmaceutical Treatments.....	81
Psychostimulant Medication.....	81
Non-stimulant Medication.....	81
Antidepressant/Antianxiety Medications.....	81
Antipsychotic Medication.....	82
Mood Stabilizing Medication.....	82
<i>TABLE 39 SELECTED PRESCRIPTION MEDICATIONS FOR TREATING ADHD.....</i>	<i>83</i>
<i>TABLE 39 (CONTINUED).....</i>	<i>84</i>
<i>TABLE 40 PRESCRIPTION MEDICATIONS FOR TREATING ADHD, IN CHILDREN UNDER AGE 18.....</i>	<i>84</i>
<i>TABLE 40 (CONTINUED).....</i>	<i>85</i>
Global Market for ADHD Treatments.....	85
<i>TABLE 41 GLOBAL MARKET FOR PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>85</i>
<i>TABLE 42 GLOBAL MARKET FOR PEDIATRIC PRESCRIPTION ADHD MEDICATION, THROUGH 2013.....</i>	<i>86</i>
U.S. Market for ADHD Treatments.....	86
<i>TABLE 43 U.S. MARKET FOR PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>86</i>
<i>TABLE 44 U.S. MARKET FOR PEDIATRIC PRESCRIPTION ADHD MEDICATIONS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>87</i>
AUTISM SPECTRUM DISORDERS.....	87
AUTISM.....	87
<i>TABLE 45 SYMPTOMS OF AUTISM.....</i>	<i>88</i>
ASPERGER'S DISORDER.....	88
CHILDHOOD DISINTEGRATIVE DISORDER.....	89
RETT'S SYNDROME.....	89
PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED.....	89
ORIGINS OF AUTISM SPECTRUM DISORDERS.....	89
Genetics.....	89
Rejected Origins of Autism Spectrum Disorders.....	90
Environmental Factors.....	90
PREVALENCE.....	91
DIAGNOSING ASD.....	91
TREATMENT FOR ASD.....	91
Psychoeducational Treatment.....	92
Medical Treatment.....	92
Dietary Changes.....	92
Vitamin Therapy.....	92
Risperidone.....	92

ECONOMIC IMPACT OF AUTISM.....	93
<i>TABLE 46 GLOBAL DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	<i>93</i>
<i>TABLE 47 GLOBAL DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATIONS IN THE PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	<i>94</i>
<i>TABLE 48 U.S. DIRECT COSTS OF AUTISM TREATMENTS AND MEDICATION IN PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	<i>94</i>
CEREBRAL PALSY.....	94
ORIGINS OF THE DISORDER.....	95
DIAGNOSING CEREBRAL PALSY	95
PREVALENCE OF CP	96
<i>TABLE 49 U.S. AVERAGE LIFETIME CEREBRAL PALSY COSTS PER PERSON, THROUGH 2013 (\$ MILLIONS)</i>	<i>97</i>
<i>TABLE 50 GLOBAL AVERAGE COSTS FOR PEDIATRIC CP PATIENTS UP TO AGE 18, THROUGH 2013 (\$ MILLIONS)</i>	<i>97</i>
<i>TABLE 51 U.S. AVERAGE COSTS FOR PEDIATRIC CP PATIENTS UPTO AGE 18, THROUGH 2013 (\$ MILLIONS)</i>	<i>98</i>
TREATMENT OF CEREBRAL PALSY	98
Therapies	98
Surgical Procedures.....	99
Medications	99
<i>TABLE 52 MEDICATIONS FOR CP PATIENTS</i>	<i>100</i>
Magnesium Sulfate.....	100
DEPRESSION.....	100
ORIGINS OF THE DISEASE.....	101
Genetic Factors	101
Biological Factors	101
Sociological Factors	102
Psychological Factors	102
Risk Factors for Depression	102
Gender	102
Age	102
Marital status	103
Family History	103
Parental Deprivation	103
Social Support	103
Family Type	103
Types of Depression	103
PREVALANCE OF THE DISORDER	104
DIAGNOSING DEPRESSION	104
<i>TABLE 53 SYMPTOMS OF DEPRESSION</i>	<i>104</i>
TREATMENT FOR DEPRESSION.....	105

<i>TABLE 54 GLOBAL DIRECT AND INDIRECT COST OF DEPRESSION, THROUGH 2013 (\$ BILLIONS)</i>	105
Therapy	106
Antidepressant Medications.....	106
<i>TABLE 55 ANTIDEPRESSANT MEDICATIONS APPROPRIATE FOR PEDIATRIC PATIENTS</i>	106
Government Warnings	107
<i>TABLE 56 GLOBAL COST OF ANTIDEPRESSANT MEDICATIONS IN PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	107
<i>TABLE 57 COST OF ANTIDEPRESSANT MEDICATION IN THE U.S. PEDIATRIC POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	108
EPILEPSY/SEIZURES	108
ORIGINS OF THE DISEASE	109
Inherited Genetic Causes	109
Congenital Causes	109
Acquired	109
<i>TABLE 58 POTENTIAL CAUSES OF EPILEPSY, BY AGE</i>	110
DIAGNOSING EPILEPSY	110
<i>TABLE 59 INTERNATIONAL CLASSIFICATION OF EPILEPTIC SEIZURES</i>	111
PREVALENCE	111
TREATMENTS.....	112
Anti-epileptic Medications	112
<i>TABLE 60 SELECTED CURRENT MEDICATIONS FOR EPILEPSY</i>	113
<i>TABLE 61 PROJECTED GLOBAL DIRECT COSTS OF EPILEPSY MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	114
<i>TABLE 62 PROJECTED GLOBAL PEDIATRIC DIRECT COSTS OF EPILEPSY MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	114
<i>TABLE 63 PROJECTED U.S. DIRECT COSTS OF EPILEPSY, THROUGH 2013 (\$ MILLIONS)</i>	115
<i>TABLE 64 PROJECTED DIRECT COSTS FOR THE U.S. PEDIATRIC EPILEPSY POPULATION, THROUGH 2013 (\$ MILLIONS)</i>	115
Vagus Nerve Stimulation	115
Surgical Options	116
The Future	116
OBESITY	116
<i>TABLE 65 PROJECTED U.S. PEDIATRIC DIRECT HEALTHCARE COSTS ATTRIBUTABLE TO OVERWEIGHT AND OBESITY, THROUGH 2013 (\$ MILLIONS)</i>	117
ORIGINS OF THE DISEASE	117
DIAGNOSING OBESITY	118
Genetic Factors	118
Environmental Factors.....	118
Behavioral Factors.....	119

PREVALENCE OF THE DISEASE	120
TREATMENT OF OBESITY	120
Healthy Food Choices	120
Dietary Restrictions.....	121
Increased Exercise	121
Pharmaceutical Products for Adolescents	122
<i>TABLE 66 GLOBAL MARKET FOR PRESCRIPTION WEIGHT LOSS</i>	
<i>PRODUCTS THROUGH 2013 (\$ MILLIONS)</i>	122
<i>TABLE 67 GLOBAL MARKET FOR PRESCRIPTION WEIGHT LOSS</i>	
<i>PRODUCTS FOR ADOLESCENTS, THROUGH 2013 (\$ MILLIONS)</i>	123
<i>TABLE 68 U.S MARKET FOR PRESCRIPTION WEIGHT LOSS</i>	
<i>PRODUCTS FOR ADOLESCENTS, THROUGH 2013 (\$ MILLIONS)</i>	123
Surgical Options	123
<i>TABLE 69 RECOMMENDED CRITERIA FOR BARIATRIC SURGERY</i>	
<i>FOR ADOLESCENTS</i>	124
<i>TABLE 70 GLOBAL MARKET FOR SURGICAL PROCEDURES FOR</i>	
<i>PEDIATRIC PATIENTS WHO ARE OBESE/OVERWEIGHT,</i>	
<i>THROUGH 2013 (\$ MILLIONS)</i>	125
<i>TABLE 71 MARKET FOR SURGICAL PROCEDURES FOR U.S.</i>	
<i>PEDIATRIC PATIENTS WHO ARE OBESE/OVERWEIGHT,</i>	
<i>THROUGH 2013 (\$ MILLIONS)</i>	125
Complications	126
GLOBAL TRENDS.....	126
<i>TABLE 72 PROJECTED GLOBAL PEDIATRIC DIRECT HEALTHCARE</i>	
<i>COSTS ATTRIBUTABLE TO OVERWEIGHT AND OBESITY (\$</i>	
<i>MILLIONS)</i>	127
RESPIRATORY ILLNESSES.....	127
ALLERGIES.....	127
ORIGINS OF THE DISEASE	127
Airborne Allergies.....	128
Food Allergies	128
<i>TABLE 73 COMMON FOOD ALLERGENS</i>	129
Sinusitis	129
Drug Allergy	129
Allergic Rhinitis.....	129
Diagnosing Breathing Allergies	130
Prevalence of Allergic Rhinitis	130
TREATMENT	130
Immunotherapy	130
Environmental Measures	131
Antihistamines	132
Cetirizine.....	132
Fexofenadine	132
Desloratadine	132

Loratadine	133
Mast Cell Stabilizers	133
Anti-IgE Antibody	133
<i>TABLE 74 COMMON ALLERGY MEDICATIONS APPROPRIATE FOR CHILDREN</i>	<i>133</i>
<i>TABLE 74 (CONTINUED)</i>	<i>134</i>
COSTS	134
<i>TABLE 75 GLOBAL DIRECT COSTS OF ALLERGIES, THROUGH 2013 (\$ MILLIONS)</i>	<i>135</i>
<i>TABLE 76 DIRECT COSTS OF ALLERGIES IN THE U.S., THROUGH 2013 (\$ MILLIONS)</i>	<i>135</i>
<i>TABLE 77 GLOBAL DIRECT COSTS OF PEDIATRIC ALLERGIES, THROUGH 2013 (\$ MILLIONS)</i>	<i>135</i>
<i>TABLE 78 DIRECT COSTS OF U.S. PEDIATRIC ALLERGIES, THROUGH 2013 (\$ MILLIONS)</i>	<i>136</i>
ASTHMA	136
ORIGINS OF THE DISEASE	136
DIAGNOSING ASTHMA.....	137
Exercise	137
Infections.....	138
Allergies	138
Irritants.....	138
Weather.....	138
Emotions	138
PREVALENCE OF ASTHMA.....	139
TREATMENTS.....	139
<i>TABLE 79 FOUR-STEP GUIDELINES FOR TREATING ASTHMA IN CHILDREN UNDER THE AGE OF FIVE</i>	<i>140</i>
<i>TABLE 80 FOUR-STEP GUIDELINES FOR TREATING ASTHMA IN CHILDREN OVER THE AGE OF FIVE</i>	<i>140</i>
<i>TABLE 81 QUICK-ACTING MEDICATIONS FOR ASTHMA</i>	<i>141</i>
Inhaled Corticosteroids	141
<i>TABLE 82 SELECTED LISTING OF INHALED CORTICOSTEROIDS</i>	<i>141</i>
COSTS	142
<i>TABLE 83 GLOBAL COSTS FOR ASTHMA MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	<i>142</i>
<i>TABLE 84 U.S. COSTS FOR ASTHMA MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	<i>142</i>
<i>TABLE 85 GLOBAL COSTS FOR PEDIATRIC ASTHMA MEDICATIONS, THROUGH 2013 (\$ MILLIONS)</i>	<i>143</i>
<i>TABLE 86 COSTS FOR PEDIATRIC ASTHMA MEDICATIONS IN THE U.S., THROUGH 2013 (\$ MILLIONS)</i>	<i>143</i>
CHAPTER SIX: CURRENT RESEARCH.....	144
ALLERGIES.....	144

SCHERING-PLOUGH	144
Allergy immunotherapy	144
ASTHMA	144
7TM.....	144
GENENTECH	145
Xolair.....	145
Anti-IL13.....	145
ASTRAZENECA.....	145
Medimmune	145
Anti-IL13 MAb (CAT-354).....	145
Anti-IL9 MAb (MEDI 528).....	145
MAP PHARMACEUTICALS	146
SCHERING-PLOUGH	146
Nasal Inhaled Combinations.....	146
Pleconaril	146
ASTHMATX.....	146
Bronchial Thermoplasty.....	146
TOPIGEN PHARMACEUTICALS	147
SYNAIRGEN	147
VECTURA PLC	147
ATTENTION DEFICIT/ATTENTION DEFICIT HYPERACTIVITY	
DISORDER	148
SHIRE US.....	148
Intuniv.....	148
SOMERSET PHARMACEUTICALS.....	148
Selegiline.....	148
CEPHALON	148
Modafinil	148
CEREBRAL PALSY.....	148
GENETIC CAUSES OF CP	149
STEM CELL RESEARCH	149
CYSTIC FIBROSIS.....	149
GENE THERAPY.....	149
Copernicus Therapeutics.....	149
INFECTIOUS	150
Aradigm Corp.....	150
ENZYME REPLACEMENT.....	150
Altus Pharmaceuticals	150
Eurand	150
IMPROVED HYDRATION/SALT TRANSPORT.....	151
Lantiobio, Inc.....	151
Sucampo Pharmaceuticals	151
Inspire Pharmaceuticals	151
Pharmaxis.....	152

Gilead Sciences	152
PROTEIN PRODUCTION	152
PTC Therapeutics	152
Vertex Pharmaceuticals	152
INHALATION THERAPY	153
Vectura PLC.....	153
DEPRESSION	153
FOREST LABORATORIES	153
F2695.....	153
Lexapro	153
SANOFI AVENTIS.....	154
Saredutant	154
SEPRACOR	154
SEP-225289.....	154
SEP-227162.....	154
DIABETES	154
INHALATION INSULIN	154
Generex Biotechnology	154
Coromed, Inc.	155
Nastech Pharmaceuticals.....	155
Mannkind Corporation	156
MAP Pharmaceuticals	156
Vectura PLC.....	157
TRANSDERMAL INSULIN DELIVERY	157
Dermasonics.....	157
Medingo.....	157
Vyteris	157
BLOOD GLUCOSE MONITORING.....	158
Abbott Laboratories.....	158
LONGER-LASTING INSULINS	158
Novo Nordisk	158
FOREST LABORATORIES	158
COMBINATION DRUG THERAPIES	159
Novartis/Pfizer.....	159
Gleevec/Sutent	159
Merck.....	159
Januvia/metformin	159
ORAL DIABETIC AGENTS.....	159
Generex Biotechnology	159
EAR INFECTIONS	160
EPILEPSY/SEIZURES	160
UCB PHARMACEUTICALS	160
Brivaracetam	160
JOHNSON & JOHNSON.....	160

Carisbamate(RWJ-333369)	160
2 DIOXY-D-GLUCOSE RESEARCH.....	161
SEPRACOR	161
Eslicarbanzepine acetate (BIA-2-093)	161
SCHWARZ BIOSCIENCES	161
Lacosamide	161
JAZZ PHARMACEUTICALS.....	162
JZP-4	162
HUPERZINE A.....	162
NEUROADJUVANTS	162
NAX-5055.....	162
Propylisopropylacetamide (PID)	163
MARINUS PHARMACEUTICALS	163
Ganaxolone	163
VALEANT PHARMACEUTICALS	163
Retigabine	163
TARO PHARMACEUTICALS	164
T-2000	164
OBESITY	164
DRUGS MARKETED FOR OTHER CONDITIONS	164
OBESITY DRUG PIPELINE.....	165
Sanofi Aventis.....	165
Phytopharm	165
Arena Pharma.....	165
7TM	165
7TM (Continued).....	166
CHAPTER SEVEN: COMPANY PROFILES	167
7TM PHARMA A/S	167
BUSINESS OVERVIEW.....	167
FINANCIAL OVERVIEW.....	167
PRODUCTS.....	167
ABBOTT LABORATORIES.....	168
ABBOTT LABORATORIES.....	168
FINANCIAL INFORMATION.....	168
PRODUCTS	168
ALTUS PHARMACEUTICALS.....	169
BUSINESS OVERVIEW.....	169
FINANCIAL INFORMATION.....	169
PRODUCTS	169
ARADIGM CORPORATION	170
BUSINESS OVERVIEW.....	170
FINANCIAL INFORMATION.....	170
PRODUCTS.....	170
ARENA PHARMACEUTICALS.....	170

BUSINESS OVERVIEW.....	171
FINANCIAL INFORMATION.....	171
PRODUCTS.....	171
ASTRAZENECA PLC.....	171
BUSINESS OVERVIEW.....	171
FINANCIALS.....	172
PRODUCTS.....	172
AVONTEC GMBH.....	172
BUSINESS OVERVIEW.....	172
FINANCIAL INFORMATION.....	172
PRODUCTS.....	173
AXCAN PHARMA USA.....	173
BUSINESS OVERVIEW.....	173
FINANCIAL INFORMATION.....	173
PRODUCTS.....	173
BAYER AG (MILES-BAYER).....	174
BUSINESS OVERVIEW.....	174
FINANCIAL INFORMATION.....	174
PRODUCTS.....	174
CHIESI FARMACEUTICI S.P.A.....	174
BUSINESS OVERVIEW.....	174
FINANCIAL INFORMATION.....	175
PRODUCTS.....	175
COPERNICUS THERAPEUTICS, INC.....	176
BUSINESS OVERVIEW.....	176
FINANCIAL INFORMATION.....	176
PRODUCTS.....	176
COROMED, INC.....	177
BUSINESS OVERVIEW.....	177
FINANCIAL INFORMATION.....	177
PRODUCTS.....	177
ELI LILLY.....	178
BUSINESS OVERVIEW.....	178
FINANCIAL INFORMATION.....	178
PRODUCTS.....	178
EURAND PHARMACEUTICALS.....	178
BUSINESS OVERVIEW.....	179
FINANCIAL INFORMATION.....	179
PRODUCTS.....	179
GENENTECH INC.....	179
BUSINESS OVERVIEW.....	180
FINANCIAL INFORMATION.....	180
PRODUCTS.....	180
GENEREX BIOTECHNOLOGY.....	180

BUSINESS OVERVIEW.....	180
FINANCIAL INFORMATION.....	181
PRODUCTS.....	181
GILEAD SCIENCES.....	181
BUSINESS OVERVIEW.....	181
FINANCIAL INFORMATION.....	181
PRODUCTS.....	181
GLAXOSMITHKLINE PLC.....	182
BUSINESS OVERVIEW.....	182
FINANCIAL INFORMATION.....	182
PRODUCTS.....	182
INSPIRE PHARMACEUTICALS, INC.....	183
BUSINESS OVERVIEW.....	183
FINANCIAL INFORMATION.....	183
PRODUCTS.....	183
JOHNSON & JOHNSON.....	184
BUSINESS OVERVIEW.....	184
FINANCIAL INFORMATION.....	184
PRODUCTS.....	184
KALOBIOS PHARMACEUTICALS, INC.....	185
BUSINESS OVERVIEW.....	185
FINANCIAL INFORMATION.....	185
PRODUCTS.....	185
LANTIBIO, INC.....	186
BUSINESS OVERVIEW.....	186
FINANCIAL INFORMATION.....	186
PRODUCTS.....	186
MANKIND CORP.....	186
BUSINESS OVERVIEW.....	187
FINANCIAL INFORMATION.....	187
PRODUCTS.....	187
MAP PHARMAEUTICALS.....	188
BUSINESS OVERVIEW.....	188
FINANCIAL INFORMATION.....	188
PRODUCTS.....	188
MERCK & CO INC.....	189
BUSINESS OVERVIEW.....	189
FINANCIAL INFORMATION.....	189
PRODUCTS.....	189
NOVARTIS AG.....	190
BUSINESS OVERVIEW.....	190
FINANCIAL INFORMATION.....	190
PRODUCTS.....	190
NOVO NORDISK.....	190

BUSINESS OVERVIEW.....	191
FINANCIAL OVERVIEW.....	191
PRODUCTS.....	191
NUTRISET.....	191
BUSINESS OVERVIEW.....	191
FINANCIAL OVERVIEW.....	192
PRODUCTS.....	192
PFIZER.....	192
BUSINESS OVERVIEW.....	192
FINANCIAL INFORMATION.....	192
PRODUCTS.....	193
PHARMAXIS, LTD.....	193
BUSINESS OVERVIEW.....	193
FINANCIAL INFORMAITON.....	193
PRODUCTS.....	193
PHYTOPHARM, PLC.....	194
BUSINESS OVERVIEW.....	194
FINANCIAL INFORMATION.....	194
PRODUCTS.....	194
PTC THERAPEUTICS.....	194
BUSINESS OVERVIEW.....	195
FINANCIAL INFORMATION.....	195
PRODUCTS.....	195
ROCHE PHARMACEUTICALS.....	195
BUSINESS OVERVIEW.....	195
FINANCIAL INFORMATION.....	196
PRODUCTS.....	196
SANOFI-AVENTIS.....	196
BUSINESS OVERVIEW.....	196
FIANCIAL INFORMATION.....	196
PRODUCTS.....	197
SCHERING-PLOUGH.....	197
BUSINESS OVERVIEW.....	197
FINANCIAL INFORMATION.....	197
PRODUCTS.....	197
SEPRACOR.....	198
BUSINESS OVERVIEW.....	198
FINANCIAL INFORMATION.....	198
PRODUCTS.....	198
SHIRE U.S.....	199
BUSINESS OVERVIEW.....	199
FINANCIAL INFORMATION.....	199
PRODUCTS.....	199
SOLVAY PHARMACEUTICALS.....	199

BUSINESS OVERVIEW.....	199
FINANCIAL INFORMATION.....	200
PRODUCTS.....	200
SUCAMPO PHARMACEUTICALS.....	200
BUSINESS OVERVIEW.....	200
FINANCIAL INFORMATION.....	200
PRODUCTS.....	201
SYNAIRGEN PLC.....	201
BUSINESS OVERVIEW.....	201
FINANCIAL INFORMATION.....	201
PRODUCTS.....	202
TOPIGEN PHARMACEUTICALS INC.....	202
BUSINESS OVERVIEW.....	202
FINANCIAL INFORMATION.....	202
PRODUCTS.....	202
UCB PHARMACEUTICALS.....	203
BUSINESS OVERVIEW.....	203
FINANCIAL INFORMATION.....	203
PRODUCTS.....	203
VECTURA GROUP PLC.....	204
BUSINESS OVERVIEW.....	204
FINANCIAL INFORMATION.....	204
PRODUCTS.....	204
VERTEX PHARMACEUTICALS.....	205
BUSINESS OVERVIEW.....	205
FINANCIAL INFORMATION.....	205
PRODUCTS.....	205
WYETH.....	206
BUSINESS OVERVIEW.....	206
FINANCIAL INFORMATION.....	206
PRODUCTS.....	206
APPENDIX: SELECTED PEDIATRIC PRODUCTS BY ILLNESS.....	207
<i>TABLE 87 SELECTED PEDIATRIC PRODUCTS BY ILLNESS.....</i>	<i>207</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>208</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>209</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>210</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>211</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>212</i>
<i>TABLE 87 (CONTINUED).....</i>	<i>213</i>